All participants: - Body Mass Index 18.0 to 40.0 kilogram per meter square (kg/m^2), inclusive, and body weight >=45 kg. - Negative hepatitis B surface antigen (HBsAg) test - Positive hepatitis B surface antibody (HBsAb) test or negative HBsAb - Negative HIV (Human Immunodeficiency Virus) test - Females will not be pregnant or breastfeeding and must be either postmenopausal or surgically sterile - Males will agree to use contraception and will refrain from sperm donation Healthy participants (Cohort 1): - Negative hepatitis C virus (HCV) antibody test or positive HCV antibody test followed by a negative HCV RNA test - Normal hepatic function and no history of clinically significant hepatic dysfunction Participants with Hepatic Impairment (Cohorts 2 and 3): - Considered to have moderate (Child-Pugh score of 7 to 9) or severe (Child-Pugh score of 10 to 15) hepatic impairment - Chronic, stable hepatic insufficiency with features of cirrhosis - Negative hepatitis C viral load

All participants: - History of Type 1 diabetes or Type 2 Diabetes that is insulin-dependent or requires ongoing systemic treatment with two or more agents - Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder - Significant illness, surgery, or hospitalization within 2 weeks prior to dosing. - History of gastro-intestinal surgery - Malabsorption syndrome or any other condition that would interfere with enteral absorption. - History of active or latent Mycobacterium tuberculosis (TB), regardless of treatment history, or positive QuantiFERON® TB Gold test - History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance - Use of drugs of abuse (including opioids) Healthy participants (Cohort 1): - History of alcoholism or drug addiction Participants with Hepatic Impairment (Cohorts 2 and 3): - Hepatic impairment due to hepatocellular carcinoma or bile duct cancer - Surgical or artificial portosystemic shunt (e.g., transjugular intrahepatic portosystemic shunt) - Evidence of hepatorenal syndrome - Ascites requiring paracentesis - Any evidence of progressive liver disease in the last 1 month - Receipt of a liver transplant - Hepatic encephalopathy Grade 2 or above